RHRaphaël Helaers

Raphaël Helaers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Raphaël Helaers has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DoAggregate: a pipeline for aggregation testing for rare-variant on a gene and pathway level

    by Simon Boutry, Cédric Van Marcke, Nisha Limaye, Guillaume Smits, Pascal Brouillard, Martina De Bortoli, Eleonore Pairet, Ali Saadat, Raphaël Helaers, Jacques Fellay, et al.

    Motivation: Aggregation tests overcome the classical limitation of rare variant analysis in cohort study design. Choosing the right statistical test remains one of the biggest challenges. Existing tools fall short in offering a comprehensive solution that includes automatic data processing, testing across all genes, as well as exploration of broader genetic regions such as pathways and Gene Ontology (GO) terms. Most aggregation tests only report p-values and basic statistics, lacking in the presentation of cohort level statistics and comparison of results across whole genome or exome scales. Results: We introduce DoAggregate, an innovative, scalable pipeline designed to address these challenges. DoAggregate enables users to perform aggregation tests across genes, pathways, and GO terms. It leverages Excalibur, an ensemble approach combining 36 distinct aggregation methods. The pipeline enhances data analysis by presenting over-representation analysis and aggregation results in detailed Excel sheets, complete with annotations and plots to facilitate nuanced interpretation and comparison. Applied to public exome data from the 1000 Genomes Project, DoAggregate tested 10,447 genes, 49 over-represented pathways and 36 over-represented GO terms in a single run, returning annotated, cohort-level results for each region. Availability and implementation: DoAggregate source code, documentation and installation instructions as well as test data sets and results are freely available at https://github.com/boutrys/DoAggregate and released under the MIT license. The repository contains the serial implementation (R package), the parallel implementation for Slurm-based computer clusters and the web application. Supplementary information: Supplementary data are available online.

  • Open Access

    Mixed acid fermentation products from Lachnospira eligens counteract myotube atrophy

    by Sophie Lecop, Edwige Piron, Audrey M. Neyrinck, Axelle Loriot, Sarah A. Pötgens, Raphaël Helaers, Amandine Jacquet, Pauline Morigny, Eleonora Scorletti, Josh Bilson, et al.

    Introduction. Acute myeloid leukemia (AML) is a hematological malignancy associated with muscle wasting. As the relative abundance of Lachnospira eligens was reduced in patients with AML compared to healthy individuals and correlated positively with muscle strength, we hypothesized that L. eligens positively impacts the muscle through the production of small metabolites reaching the systemic circulation. Methods. L. eligens levels were analyzed in two additional independent cohorts. Six L. eligens isolates were characterized through whole-genome sequencing to select clinically relevant strains. The composition of their culture supernatant was analyzed by metabolomics. The impact of L. eligens supernatant on dexamethasone- and interleukin-6-atrophied murine myotubes was assessed. Bioactive metabolites and their production mechanism were identified using among others bioactivity-guided fractionation. The underlying mechanism was also explored on the host side through myotubes′ transcriptome analysis and metabolic flux analysis. The relevance of bioactive metabolites and their production mechanism was evaluated through clinical data and samples analyses and in a mouse model of leukemia. Results. The levels of L. eligens are reduced in independent cohorts of patients with AML and its supernatant counteracts myotube atrophy. This anti-atrophic effect, conserved between strains of the same species, depends on the occurrence of mixed acid fermentation (MAF) in anoxic culture conditions and the presence of its acid end-products acetate, formate and D-lactate. Consistent with those results, blood levels of acetate are decreased and the relative abundance of fecal bacteria capable of performing aerobic respiration is increased in patients with AML. However, bacterial supernatant failed to prevent muscle atrophy and weakness in leukemic mice, likely due to insufficient sustained elevation of acid end-products in the blood. Conclusion. This work reveals the anti-atrophic effect of MAF end-products on myotubes and suggests the importance of considering gut electron acceptor levels (e.g. O 2 ) in disorders affecting muscle health.

  • Open Access

    Clinical Characterization of Atypical Diabetes: Insights from the GENEPEDIAB Study into the Spectrum Between Type 1 and Monogenic Diabetes

    by Antoine Harvengt, Gauthier Pirlot, Leyan Denizli, Zain Syed, Sophie Welsch, Dominique Beckers, Thierry Mouraux, Nicole Seret, Marie-Christine Lebrethon, Raphael Helaers, et al.

    Background: Type 1 diabetes (T1D) shares clinical characteristics with other forms of diabetes, particularly monogenic diabetes such as maturity-onset diabetes of the young (MODY). Differential diagnosis is complicated by the existence of intermediate phenotypes. We aimed to delineate the phenotypic continuum between T1D and monogenic diabetes. Methods: The multicentric GENEPEDIAB study included patients aged 6 months to 18 years diagnosed with diabetes and treated for either T1D or monogenic diabetes. Analyses comprised glycemic variability, continuous glucose monitoring metrics, application of the DIAMODIA criteria, and genetic investigations. Results: A gradient was observed across T1D, atypical diabetes (Adia), and MODY cohorts for several glycemic parameters. T1D patients exhibited values furthest from treatment targets, whereas MODY patients showed better glycemic control. Stratification of the Adia cohort according to the number of positive DIAMODIA criteria further supported this trend, as demonstrated by glycemic measures and multiple correspondence analysis. Genetic analyses did not identify a uniform causative variant in the Adia cohort; however, several rare variants, including variants of uncertain significance and likely pathogenic variants in diabetes-related genes, were detected. Conclusions: These findings showed, in our specific cohort of pediatric patients, the existence of a phenotypic gradient between T1D and monogenic diabetes, with atypical diabetes occupying an intermediate position, including when stratified by DIAMODIA criteria.

  • Open Access

    Likely Pathogenic/Pathogenic Variants in the Spliceosome Complex Genes SNRNP200, SF3B1, SF3B2, and SF3B4 Implicated in Nonsyndromic Orofacial Cleft

    by Peyman Ranji, Eleonore Pairet, Raphael Helaers, Pascal Brouillard, Bénédicte Bayet, Alexander Gerdom, Nicole Revencu, Miikka Vikkula

    The genetic basis of nonsyndromic orofacial cleft (NsOFC) remains elusive, although associations have been identified with various genetic loci. NsOFC has a less pronounced genetic background than syndromic orofacial cleft (SyOFC), albeit Mendelian inheritance has been identified. Our hypothesis was that genes related to spliceosome function may contribute to NsOFC pathophysiology, as they do for some syndromic cases. Exome sequencing was conducted on 224 unrelated NsOFC probands. We performed filtering and analyses of predicted pathogenicity of rare variants using Highlander. We focused on 26 genes encoding spliceosome proteins. Subsequently, bioinformatic tools, such as AlphaFold, and PyMol, were applied to generate three‐dimensional structures to interpret the effects of the identified variants on protein structure and interaction domains. We found six likely damaging variants: three heterozygous missense variants in small nuclear ribonucleoprotein U5 200 kDa subunit ( SNRNP200 ) in three multiplex NsOFC families, and two missense and one splice site variant in splicing factor 3b subunit 1 ( SF3B1 ), 4 ( SF3B4 ), and 2 ( SF3B2 ) in two posterior CP families and a complete CP patient, respectively. These results suggest that variants in the spliceosome complex genes, observed in 2.7% of NsOFC cases in our cohort, may contribute to disease susceptibility as potential risk factors.

  • Whole exome sequencing in 18 Brazilian families with vertical transmission of non-syndromic oral clefts

    by Matheus de Mello Copelli, Milena Atique-Tacla, Eleonore Pairet, Gabriela Roldão Correia-Costa, Tiago Henrique de Souza, Isabella Lopes Monlleó, Társis Paiva Vieira, Raphaël Helaers, Miikka Vikkula, Vera Lúcia Gil-Da-Silva-Lopes


  • Open Access

    Four putative pathogenic ARHGAP29 variants in patients with non-syndromic orofacial clefts (NsOFC)

    by Peyman Ranji, Eleonore Pairet, Raphael Helaers, Bénédicte Bayet, Alexander Gerdom, Vera Lúcia Gil-Da-Silva-Lopes, Nicole Revencu, Miikka Vikkula

    The pathophysiological basis of non-syndromic orofacial cleft (NsOFC) is still largely unclear. However, exome sequencing (ES) has led to identify several causative genes, often with reduced penetrance. Among these, the Rho GTPase activating protein 29 (ARHGAP29) has been previously implicated in 7 families with NsOFC. We investigated a cohort of 224 NsOFCs for which no genetic pathogenic variant had been identified by diagnostic testing. We used ES and bioinformatic variant filtering and identified four novel putative pathogenic variants in ARHGAP29 in four families. One was a missense variant leading to the substitution of the first methionine with threonine, two were heterozygous frameshift variants leading to a premature termination codon, and one was a nonsense variant. All variants were predicted to result in loss of function, either through mRNA decay, truncated ARHGAP29, or abnormal N-terminal initiation of translation of ARHGAP29. The truncated ARHGAP29 proteins would lack the important RhoGAP domain. The variants were either absent or rare in the control population databases, and the loss of intolerance score (pLI) of ARHGAP29 is 1.0, suggesting that ARHGAP29 haploinsufficiency is not tolerated. Phenotypes ranged from microform cleft lip (CL) to complete bilateral cleft lip and palate (CLP), with one unaffected mutation carrier. These results extend the mutational spectrum of ARHGAP29 and show that it is an important gene underlying variable NsOFC phenotypes. ARHGAP29 should be included in diagnostic genetic testing for NsOFC, especially familial cases, as it may be mutated in ∼4% of them (4/97 in our cohort) with high penetrance (89%).


  • Open Access

    Four Loss of Function Pathogenic Variants in ARHGAP29 in Non-Syndromic Cleft Lip and Palate

    by Miikka Vikkula, Peyman Ranji, Eleonore Pairet, Raphael Helaers, Bénédicte Bayet, Alexander Gerdom, Vera Lucia Gil da Silva Lopes, Nicole Revencu

    The pathophysiological basis of non-syndromic cleft lip and/or palate (NsCL/P) is still largely unclear. However, exome sequencing (ES) has allowed to associate several genes with NsCL/P, often with reduced penetrance. Among these genes, the Rho GTPase activating protein 29 (ARHGAP29) has been previously implicated in 7 families with NsCL/P. We investigated a cohort of 224 NsCLPs for which no genetic mutation had been identified by diagnostic testing. We used ES and bioinformatic variant filtering and identified four novel likely pathogenic/pathologic variants in ARHGAP29 in four multiplex families. One was a missense variant leading to the substitution of the first methionine with threonine, two were heterozygous frameshift variants leading to a premature termination codon, and the last one was a nonsense variant. All variants were predicted to result in loss of function, either through NMD-mediated mRNA decay, or by truncated ARHGAP29, or by non-translation or abnormal N-terminal initiation of translation of ARHGAP29. The truncated ARHGAP29 proteins would lack the important RhoGAP domain. The variants were not present in the control population databases, and the loss of intolerance score (pLI) of ARHGAP29 is 1.0, suggesting that ARHGAP29 haploinsufficiency is not tolerated. Phenotypes ranged from microform CL to complete bilateral CLP, with one unaffected mutation carriers. These results extend the mutational spectrum of ARHGAP29 and show that it is an important gene underlying variable NsCL/P phenotypes. ARHGAP29 should be included in diagnostic genetic testing for NsCL/P, especially familial cases, as it may be mutated in ⁓2% of patients with high penetrance (88%).

  • Open Access

    Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV)

    by Martina De Bortoli, Angela Queisser, Van Cuong Pham, Anne Dompmartin, Raphaël Helaers, Simon Boutry, Cathy Claus, An-Katrien De Roo, Frank Hammer, Pascal Brouillard, et al.


  • Open Access

    Epilepsy with faint capillary malformation or reticulated telangiectasia associated with mosaic AKT3 pathogenic variants

    by Martina De Bortoli, Marta Ivars, Nicole Revencu, Marie‐Cécile Nassogne, Cinzia Lavarino, Sonia Paco, Martin Lammens, Anne Renders, Dana Dumitriu, Raphaël Helaers, et al.

    Capillary malformations (CMs) are the most common type of vascular anomalies, affecting around 0.3% of newborns. They are usually caused by somatic pathogenic variants in GNAQ or GNA11. PIK3CA and PIK3R1, part of the phosphoinositide 3‐kinase–protein kinase B–mammalian target of rapamycin pathway, are mutated in fainter CMs such as diffuse CM with overgrowth and megalencephaly CM. In this study, we present two young patients with a CM‐like phenotype associated with cerebral anomalies and severe epilepsy. Pathogenic variants in PIK3CA and PIK3R1, as well as GNAQ and GNA11, were absent in affected cutaneous tissue biopsies. Instead, we identified two somatic pathogenic variants in the AKT3 gene. Subsequent analysis of the DNA obtained from surgically resected brain tissue of one of the two patients confirmed the presence of the AKT3 variant. Focal cortical dysplasia was also detected in this patient. Genetic analysis thus facilitated workup to reach a precise diagnosis for these patients, associating the vascular anomaly with the neurological symptoms. This study underscores the importance of searching for additional signs and symptoms to guide the diagnostic workup, especially in cases with atypical vascular malformations. In addition, it strongly emphasizes the significance of genotype–phenotype correlation studies in guiding clinicians' informed decision‐making regarding patient care.


  • Molecular investigation in individuals with orofacial clefts and microphthalmia-anophthalmia-coloboma spectrum

    by Milena Atique Tacla, Matheus de Mello Copelli, Eleonore Pairet, Isabella Lopes Monlleó, Erlane Marques Ribeiro, Elaine Lustosa Mendes, Raphaël Helaers, Tarsis Paiva Vieira, Miikka Vikkula, Vera Lúcia Gil-Da-Silva-Lopes

    This study describes genomic findings among individuals with both orofacial clefts (OC) and microphthalmia/anophthalmia/coloboma (MAC) recorded in the Brazilian Database on Craniofacial Anomalies (BDCA). Chromosomal microarray analysis (CMA) and Whole Exome Sequencing (WES) were performed in 17 individuals with OC-MAC. Clinical interpretation of molecular findings was based on data available at the BDCA and on re-examination. No copy number variants (CNVs) classified as likely pathogenic or pathogenic were detected by CMA. WES allowed a conclusive diagnosis in six individuals (35.29%), two of them with variants in the CHD7 gene, and the others with variants in the TFAP2A, POMT1, PTPN11, and TP63 genes with the following syndromes: CHARGE, CHD7-spectrum, Branchiooculofacial, POMT1-spectrum, LEOPARD, and ADULT. Variants of uncertain significance (VUS) possibly associated to the phenotypes were found in six other individuals. Among the individuals with VUSes, three individuals presented variants in genes associated to defects of cilia structure and/or function, including DYNC2H1, KIAA0586, WDR34, INTU, RPGRIP1L, KIF7, and LMNA. These results show that WES was the most effective molecular approach for OC-MAC in this cohort. This study also reinforces the genetic heterogeneity of OC-MAC, and the importance of genes related to ciliopathies in this phenotype.